Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF; EVALUATE-HF Investigators.

JAMA. 2019 Sep 2:1-10. doi: 10.1001/jama.2019.12843. [Epub ahead of print]

PMID:
31475296
2.

Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism.

Izzo JL Jr, Hong M, Hussain T, Osmond PJ.

J Clin Hypertens (Greenwich). 2019 Aug;21(8):1183-1190. doi: 10.1111/jch.13597. Epub 2019 Jul 26.

3.

Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy.

Izzo JL Jr, Hong M, Hussain T, Osmond PJ.

J Clin Hypertens (Greenwich). 2019 Jul;21(7):922-928. doi: 10.1111/jch.13567. Epub 2019 Jun 6.

4.

Pulse Wave Velocities Derived From Cuff Ambulatory Pulse Wave Analysis.

Schwartz JE, Feig PU, Izzo JL Jr.

Hypertension. 2019 Jul;74(1):111-116. doi: 10.1161/HYPERTENSIONAHA.119.12756. Epub 2019 May 28.

PMID:
31132952
5.

Transition state analysis of an enantioselective Michael addition by a bifunctional thiourea organocatalyst.

Izzo JA, Myshchuk Y, Hirschi JS, Vetticatt MJ.

Org Biomol Chem. 2019 Apr 17;17(16):3934-3939. doi: 10.1039/c9ob00072k.

PMID:
30942247
6.

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.

Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, Seman L.

Circulation. 2019 Apr 30;139(18):2098-2109. doi: 10.1161/CIRCULATIONAHA.118.036568.

PMID:
30786754
7.

Barriers to blood pressure control initiatives: Regional diversity, inadequate measurement techniques, guideline inconsistencies, and health disparities.

Izzo JL Jr.

J Clin Hypertens (Greenwich). 2019 Feb;21(2):204-207. doi: 10.1111/jch.13466. Epub 2019 Jan 4. No abstract available.

8.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer.

Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG.

Oncotarget. 2018 Sep 21;9(74):33995-34008. doi: 10.18632/oncotarget.26129. eCollection 2018 Sep 21.

9.

Diagnostic accuracy of a rapid telemedicine encounter in the Emergency Department.

Izzo JA, Watson J, Bhat R, Wilson M, Blumenthal J, Houser C, Descallar E, Hoffman D, Booker E.

Am J Emerg Med. 2018 Nov;36(11):2061-2063. doi: 10.1016/j.ajem.2018.08.022. Epub 2018 Aug 7.

PMID:
30209006
10.

Isotope Effects Reveal an Alternative Mechanism for "Iminium-Ion" Catalysis.

Izzo JA, Poulsen PH, Intrator JA, Jørgensen KA, Vetticatt MJ.

J Am Chem Soc. 2018 Jul 11;140(27):8396-8400. doi: 10.1021/jacs.8b04856. Epub 2018 Jun 29.

11.

Predictors for the development of microalbuminuria and interaction with renal function.

Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope LM, Rump C, Mertens PR, Haller H.

J Hypertens. 2017 Dec;35(12):2501-2509. doi: 10.1097/HJH.0000000000001491.

PMID:
29035939
12.

HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo.

Jin J, Grimmig B, Izzo J, Brown LAM, Hudson C, Smith AJ, Tan J, Bickford PC, Giunta B.

Cell Transplant. 2016 Nov;25(11):1967-1977. doi: 10.3727/096368916X691457.

13.

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG.

Mol Cancer Ther. 2017 Oct;16(10):2234-2245. doi: 10.1158/1535-7163.MCT-17-0148. Epub 2017 Jul 20.

14.

Pyro-Borates, Spiro-Borates, and Boroxinates of BINOL-Assembly, Structures, and Reactivity.

Hu G, Gupta AK, Huang L, Zhao W, Yin X, Osminski WEG, Huang RH, Wulff WD, Izzo JA, Vetticatt MJ.

J Am Chem Soc. 2017 Aug 2;139(30):10267-10285. doi: 10.1021/jacs.7b02317. Epub 2017 Jul 19.

PMID:
28657739
15.

Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.

Izzo JL Jr, Zappe DH, Jia Y, Hafeez K, Zhang J.

J Cardiovasc Pharmacol. 2017 Jun;69(6):374-381. doi: 10.1097/FJC.0000000000000485.

PMID:
28338503
16.

Response to "A Short Insight on Two Different Aspects of Arterial Stiffness"; Moving Forward or Backward?

Izzo JL Jr, Gavish B.

Am J Hypertens. 2017 Apr 1;30(4):e3-e4. doi: 10.1093/ajh/hpw203. No abstract available.

PMID:
28158321
17.

Bifunctional Ammonium Salt Catalyzed Asymmetric α-Hydroxylation of β-Ketoesters by Simultaneous Resolution of Oxaziridines.

Novacek J, Izzo JA, Vetticatt MJ, Waser M.

Chemistry. 2016 Nov 21;22(48):17339-17344. doi: 10.1002/chem.201604153. Epub 2016 Oct 20.

PMID:
27763714
18.

Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.

Izzo JL Jr, Jia Y, Zappe DH.

J Clin Hypertens (Greenwich). 2017 Feb;19(2):143-150. doi: 10.1111/jch.12891. Epub 2016 Sep 1.

19.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS.

J Clin Oncol. 2016 Oct 20;34(30):3638-3647. doi: 10.1200/JCO.2015.66.0084.

20.

Hypertension and aging in rural Haiti: results from a preliminary survey.

Polsinelli VB, Satchidanand N, Singh R, Holmes D, Izzo JL Jr.

J Hum Hypertens. 2017 Feb;31(2):138-144. doi: 10.1038/jhh.2016.52. Epub 2016 Jul 28.

PMID:
27465982
21.

Controversies in hypertension: is lower blood pressure always better?

Tobe SW, Izzo JL Jr.

J Am Soc Hypertens. 2016 Aug;10(8):618-20. doi: 10.1016/j.jash.2016.06.027. Epub 2016 Jun 29. No abstract available.

PMID:
27436129
22.

Arterial Stiffness: Going a Step Beyond.

Gavish B, Izzo JL Jr.

Am J Hypertens. 2016 Nov 1;29(11):1223-1233. doi: 10.1093/ajh/hpw061.

PMID:
27405964
23.

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.

Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II.

Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. Epub 2016 Jun 1.

24.

Renal denervation for human hypertension: is there a future?

Izzo JL Jr, Tobe SW.

J Am Soc Hypertens. 2016 May;10(5):390-2. doi: 10.1016/j.jash.2016.02.016. Epub 2016 Mar 8.

PMID:
27049792
25.

Is there a preferred diuretic class for patients with renal impairment and hypertension?

Izzo JL Jr, Tobe SW.

J Am Soc Hypertens. 2016 Apr;10(4):282-4. doi: 10.1016/j.jash.2016.02.008. Epub 2016 Feb 23.

PMID:
26979914
26.

Age should not be a primary consideration in the management of hypertension.

Izzo JL Jr.

J Am Soc Hypertens. 2016 Jan;10(1):12-5. doi: 10.1016/j.jash.2015.11.003. Epub 2015 Dec 1. No abstract available.

PMID:
26850523
27.

Controversies in hypertension: rationale and approach.

Izzo J, Tobe S, Levy D.

J Am Soc Hypertens. 2016 Jan;10(1):6. doi: 10.1016/j.jash.2015.11.002. Epub 2015 Nov 24. No abstract available.

PMID:
26850521
28.

How should BP be measured in the office?

Tobe SW, Izzo JL Jr.

J Am Soc Hypertens. 2016 Mar;10(3):189-90. doi: 10.1016/j.jash.2016.01.005. Epub 2016 Jan 11. No abstract available.

PMID:
26839184
29.

Should age determine hypertension management? Recommendations from current guidelines.

Izzo JL Jr, Tobe SW.

J Am Soc Hypertens. 2016 Jan;10(1):7-9. doi: 10.1016/j.jash.2016.01.002. Epub 2016 Jan 6.

PMID:
26794655
30.

Isotope Effects Reveal the Mechanism of Enamine Formation in l-Proline-Catalyzed α-Amination of Aldehydes.

Ashley MA, Hirschi JS, Izzo JA, Vetticatt MJ.

J Am Chem Soc. 2016 Feb 17;138(6):1756-9. doi: 10.1021/jacs.5b10876. Epub 2016 Feb 4.

PMID:
26772311
31.

Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.

Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II.

Cancer Res. 2016 Feb 1;76(3):675-85. doi: 10.1158/0008-5472.CAN-15-1141. Epub 2015 Dec 16.

32.

From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma.

Ileana EE, Wistuba II, Izzo JG.

Cancer J. 2015 Sep-Oct;21(5):413-24. doi: 10.1097/PPO.0000000000000150. Review.

PMID:
26389767
33.

Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination.

Izzo JL Jr, Khan SU, Saleem O, Osmond PJ.

J Am Soc Hypertens. 2015 Jul;9(7):526-35. doi: 10.1016/j.jash.2015.03.009. Epub 2015 Mar 28.

PMID:
26116459
34.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV.

Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11.

35.

Response to "Central blood pressure physiology" a (more) critical review (Schultz et al.).

Izzo JL Jr.

Am J Hypertens. 2015 May;28(5):692. doi: 10.1093/ajh/hpv030. Epub 2015 Mar 25. No abstract available.

PMID:
25810008
36.

Brachial vs. central systolic pressure and pulse wave transmission indicators: a critical analysis.

Izzo JL Jr.

Am J Hypertens. 2014 Dec;27(12):1433-42. doi: 10.1093/ajh/hpu135. Epub 2014 Sep 18. Review.

PMID:
25233859
37.

Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease.

Cheng S, Shah AM, Albisu JP, Desai AS, Hilkert RJ, Izzo J, Oparil S, Pitt B, Solomon SD.

J Hypertens. 2014 Dec;32(12):2479-86; discussion 2486-7. doi: 10.1097/HJH.0000000000000340.

PMID:
25232755
38.

Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.

Lewin AJ, Kereiakes DJ, Chrysant SG, Izzo JL Jr, Oparil S, Lee J, Fernandez V, Melino M.

Ethn Dis. 2014 Winter;24(1):41-7.

PMID:
24620447
39.

Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function.

Cheng S, Lam C, Shah A, Claggett B, Desai A, Hilkert RJ, Izzo J, Oparil S, Pitt B, Solomon SD.

J Hypertens. 2014 Jan;32(1):174-80. doi: 10.1097/HJH.0b013e32836586da.

40.

FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G48-58. doi: 10.1152/ajpgi.00234.2013. Epub 2013 Oct 31. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G357.

41.

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.

Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G, James BP, Powis G.

Cancer Res. 2013 Jun 1;73(11):3235-47. doi: 10.1158/0008-5472.CAN-11-1433. Epub 2013 Apr 30.

42.

Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.

Lewin AJ, Izzo JL Jr, Melino M, Lee J, Fernandez V, Heyrman R.

Drugs Aging. 2013 Jul;30(7):549-60. doi: 10.1007/s40266-013-0072-1.

43.

Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.

Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Melino M, Lee J, Fernandez V, Heyrman R.

Cardiovasc Diabetol. 2012 Oct 30;11:134. doi: 10.1186/1475-2840-11-134.

44.

Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril.

Izzo JL Jr, Yedlapati SH, Faheem SM, Younus U, Osmond PJ.

J Am Soc Hypertens. 2012 Nov-Dec;6(6):399-404. doi: 10.1016/j.jash.2012.08.007. Epub 2012 Oct 26.

PMID:
23107894
45.

Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency.

Lam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, Oparil S, Aurigemma GP, Thomas JD, Pitt B, Zile MR, Solomon SD.

Eur Heart J. 2013 Mar;34(9):676-83. doi: 10.1093/eurheartj/ehs299. Epub 2012 Sep 10.

PMID:
22963833
46.

Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.

Chrysant SG, Littlejohn T 3rd, Izzo JL Jr, Kereiakes DJ, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):233-43. doi: 10.2165/11634160-000000000-00000.

PMID:
22799613
47.

Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG.

Gastrointest Cancer Res. 2012 Mar;5(2):49-57.

48.

Value of combined thiazide-loop diuretic therapy in chronic kidney disease: heart failure and renin-angiotensin-aldosterone blockade.

Izzo JL Jr.

J Clin Hypertens (Greenwich). 2012 May;14(5):344. doi: 10.1111/j.1751-7176.2012.00614.x. Epub 2012 Apr 11. No abstract available.

49.

Home and clinic blood pressure responses in elderly individuals with systolic hypertension.

Cushman WC, Duprez DA, Weintraub HS, Purkayastha D, Zappe D, Samuel R, Izzo JL Jr.

J Am Soc Hypertens. 2012 May-Jun;6(3):210-8. doi: 10.1016/j.jash.2012.03.001.

PMID:
22520932
50.

The crosstalk of mTOR/S6K1 and Hedgehog pathways.

Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC.

Cancer Cell. 2012 Mar 20;21(3):374-87. doi: 10.1016/j.ccr.2011.12.028.

Supplemental Content

Support Center